15 Years of clinical experience with bupropion HCl: From bupropion to bupropion SR to bupropion XL

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 7, Issue 3, 2005, Pages 106-113

  Fava, Maurizio ^a   Rush, A John ^b   Thase, Michael E ^c   Clayton, Anita ^d   Stahl, Stephen M ^e   Pradko, James F ^f   Johnston, J Andrew ^g  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e NEUROSCIENCE EDUCATION INSTITUTE   (United States)

^f Bay Pointe Depression Clinic   (United States)

^g Innovaa Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE;

ALLERGIC REACTION; CLINICAL PRACTICE; CONSTIPATION; DIZZINESS; DRUG EFFICACY; DRUG FORMULATION; DRUG INHIBITION; DRUG RELEASE; DRUG TOLERABILITY; HEADACHE; HUMAN; INSOMNIA; MAJOR DEPRESSION; NAUSEA; REVIEW; SEIZURE; SEXUAL DYSFUNCTION; SOMNOLENCE; TREATMENT INDICATION; WEIGHT GAIN; XEROSTOMIA;

EID: 28944435199     PISSN: 15235998     EISSN: None     Source Type: Journal    
DOI: 10.4088/pcc.v07n0305     Document Type: Review

References (71)

1. Soroko FE, Maxwell RA. The pharmacologic basis for therapeutic interest in bupropion. J Clin Psychiatry 1983;44(sec 2):67-73
2. Stahl SM. Essential Psychopharmacology. 2nd ed. New York, NY: Cambridge University Press; 2000
3. Wellbutrin (bupropion) tablets, Wellbutrin SR (bupropion), and Wellbutrin XL (bupropion). Physician's Desk Reference. Montvale, NJ: Thomson PDR: 2005:1655-1659, 1659-1663, 1663-1668
4. Dunner DL, Zisook S, Billow AA, et al. A prospective safety surveillance study for bupropion sustained release in the treatment of depression. J Clin Psychiatry 1998;59:366-373
5. Johnston JA, Fiedler-Kelly J, Glover ED, et al. Relationship between drug exposure and the efficacy and safety of bupropion sustained-release for smoking cessation. Nicotine Tob Res 2001;3:131-140
6. Depression Patient Study. New Hanover, NJ: NOP World Health; 2002
7. Ferris RM, Cooper BR, Maxwell RA. Studies of bupropion's mechanism of antidepressant activity. J Clin Psychiatry 1983;44(sec 2):74-78
8. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: depression and anxiety disorders. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; 2001:447-483
9. Ascher JA, Cole JO, Colin J-N, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995;56:395-401
10. Stahl SM, Pradko JF, Haight BR. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 2004;6:159-166
11. Dong J, Blier P. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology (Berl) 2001;155:52-57
12. Stahl SM. Essential Psychopharmacology, First Edition. New York, NY: Cambridge University Press; 1996
13. Richelson E. Synaptic effects of antidepressants. J Clin Psychopharmacol 1996;16(3 suppl 2):1S-9S
14. Yatin SM, Miller GM, Norton C, et al. Dopamine transporter-dependent induction of c-fos in HEK cells. Synapse 2002;45:52-65
15. Cooper BR, Hester TJ, Maxwell RA. Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Exp Ther 1980;215:127-134
16. Learned-Coughlin SM, Bergstrom M, Savitcheva I, et al. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry 2003;54:800-805
17. Meyer JH, Goulding VS, Wilson AA, et al. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl) 2002;163:102-105
18. Szabó Z, Àrgyelán M, Kanyó B, et al. The effect of bupropion on the activity of dopamine transporter in depression: preliminary results. Eur Neuropsychopharmacol 2003;13(suppl 4):S210. Abstract No P.1.085
19. Fabre LF, Brodie HK, Garver D, et al. A multicenter evaluation of bupropion versus placebo in hospitalized depressed patients. J Clin Psychiatry 1983;44(sec 2):88-94
20. Lineberry CG, Johnston JA, Raymond RN, et al. A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. J Clin Psychiatry 1990;51:194-199
21. Coleman CC, Cunningham LA, Foster VJ, et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained-release and sertraline treatment. Ann Clin Psychiatry 1999;11:205-215
22. Croft H, Settle E, Houser T, et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999;21:643-658
23. Feighner JP, Gardner EA, Johnston JA, et al. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry 1991;52:329-335
24. Kavoussi RJ, Segraves RT, Hughes AR, et al. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 1997;58:532-537
25. Coleman CC, King BR, Bolden-Watson C, et al. A placebo-controlled comparison on sexual functioning of bupropion SR and fluoxetine. Clin Ther 2001;23:1040-1058
26. Weihs KL, Settle EC, Batey SR, et al. Bupropion sustained-release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 2000;61:196-202
27. Mendels J, Amin MM, Chouinard G, et al. A comparative study of bupropion and amitriptyline in depressed outpatients. J Clin Psychiatry 1983;44(sec 2):118-120
28. Branconnier RJ, Cole JO, Ghazvinian S, et al. Clinical pharmacology of bupropion and imipramine in elderly depressives. J Clin Psychiatry 1983;44(sec 2):130-133
29. Masco HL, Kiev A, Holloman LC, et al. Safety and efficacy of bupropion and nortriptyline in outpatients with depression. Curr Ther Res 1994;55:851-863
30. Feighner J, Hendrickson G, Miller L, et al. Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder. J Clin Psychopharmacol 1986;6:27-32
31. Weisler RH, Johnston JA, Lineberry CG, et al. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol 1994;14:170-179
32. Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry, in press
33. Rush AJ, Trivedi MH, Carmody TJ, et al. Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsychopharmacology 2002;25:131-138
34. Weihs L, Houser T, Batey S, et al. Continuation phase treatment with bupropion SR decreases risk for relapse of depression. Biol Psychiatry 2002;51:753-761
35. Bodkin JA, Lasser RA, Wines JD Jr, et al. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 1997;58:137-145
36. Spier SA. Use of bupropion with SSRIs and venlafaxine. Depress Anxiety 1998;7:73-75
37. DeBattista C, Solvason HB, Poirier J, et al. A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. J Clin Psychopharmacol 2003;23:27-30
38. Lam RW, Hossie H, Solomons K, et al. Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. J Clin Psychiatry 2004;65:337-340
39. Ferguson J, Cunningham L, Meridith C, et al. Bupropion in tricyclic nonresponders with unipolar major depressive disorder. Ann Clin Psychiatry 1994;6:153-169
40. Stern WC, Harto-Truax N, Bauer N. Efficacy of bupropion in tricyclic-resistant or intolerant patients. J Clin Psychiatry 1983;44(sec 2):148-152
41. Fava M, Papakostas GI, Petersen T, et al. Switching to bupropion in fluoxetine-resistant major depressive disorder. Ann Clin Psychiatry 2003;15:17-22
42. Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am 2003;26:457-494
43. Dilsaver SC, Qamar AB, Del Medico VJ. The efficacy of bupropion in winter depression: results of an open trial. J Clin Psychiatry 1992;53:252-255
44. Ferry L, Johnston JA. Efficacy and safety of bupropion SR for smoking cessation: data from clinical trials and 5 years of postmarketing experience. Int J Clin Pract 2003;57:224-230
45. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997;227:1195-1202
46. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340:685-691
47. Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicenter, randomized study. Eur Heart J 2003;24:946-955
48. Tashkin DP, Kanner RK, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomized trial. Lancet 2001;357:1571-1575
49. Hays JT, Hurt RD, Rigotti NA, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. Ann Intern Med 2000;135:423-433
50. Shopsin B. Bupropion's prophylactic efficacy in bipolar affective illness. J Clin Psychiatry 1983;44(sec 2):163-169
51. Wright G, Galloway L, Kim J, et al. Bupropion in the long-term treatment of cyclic mood disorders: mood stabilizing effects. J Clin Psychiatry 1985;46:22-25
52. Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994;55:391-393
53. Guille C, Demopulos C, Sachs G. Bupropion vs desipramine in the treatment of bipolar depression [poster]. Presented at the 151st annual meeting of the American Psychiatric Association; May 30-June 4, 1998; Toronto, Ontario, Canada
54. Wender PH, Reimherr FW. Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry 1990;147:1018-1020
55. Barrickman LL, Perry PJ, Allen AJ, et al. Bupropion versus methylphenidate in the treatment of ADHD. J Am Acad Child Adolesc Psychiatry 1995;35:649-657
56. Conners CK, Casat CD, Gualtieri CT, et al. Bupropion in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1996;34:1314-1321
57. Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001;158:282-288
58. Gardner EA. Effects of bupropion on weight in patients intolerant to previous antidepressants. Curr Ther Res 1985;35:188-199
59. Gadde KM, Parker CB, Marier LG, et al. Bupropion for weight loss: investigation of efficacy and tolerability in overweight and obese women. Obes Res 2001;9:544-551
60. Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR vs placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002;10:1049-1056
61. Anderson JW, Greenway FL, Fujioka K, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002;10:633-641
62. Anderson JW, Greenway FL. The effect of bupropion sustained release on weight loss in obese adolescents [poster]. Presented at the 157th annual meeting of the American Psychiatric Association; May 1-6, 2004: New York, NY
63. Settle EC, Stahl SM, Batey SR, et al. Safety of sustained-release bupropion in depression: results of three clinical trials. Clin Ther 1999;21:454-463
64. Settle EC. Bupropion sustained release: side effect profile. J Clin Psychiatry 1998;59(suppl 4):32-36
65. Thase ME, Haight B, Hunt T, et al. Bupropion SR does not affect blood pressure of hypertensive patients [poster]. Presented at the 156th annual meeting of the American Psychiatric Association; May 17-22, 2003: San Francisco, Calif
66. Stahl SM. Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. J Clin Psychiatry 1998;59 (suppl 18):23-29
67. Fava M, Rankin M. Sexual functioning and SSRIs. J Clin Psychiatry 2002;63(suppl 5):13-16
68. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63:357-366
69. Clayton AH, Warnock JK, Kornstein SG, et al. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 2004;65:62-67
70. Clayton AH, McGarvey EL, Abouesh AI, et al. Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction. J Clin Psychiatry 2001;62:185-190
71. Croft H, Houser TL, Jamerson B, et al. Effect on body weight of bupropion SR in patients with major depression treated for 52 weeks. Clin Ther 2002;24:662-672